Ascendis Pharma A (ASND) Revenue (2014 - 2026)

For the trailing twelve months through Jun 30, 2026, Revenue at Ascendis Pharma A was $1.22 billion, up 128.4% year-over-year; for the year ended Dec 31, 2025, it came in at $813.61 million, up 85.3% from the prior year.

• Annual Revenue has increased for five consecutive years, with a five-year compound annual growth rate of 150.2% (years ended Dec 2020 to Dec 2025).
• In prior years, Ascendis Pharma A's Revenue was $439.19 million in the year ended Dec 31, 2024 (+52.2%), $288.51 million in the year ended Dec 31, 2023 (+434.9%), $53.94 million in the year ended Dec 31, 2022 (+506.2%) and $8.9 million in the year ended Dec 31, 2021 (+7.3%).
• The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly Revenue in data going back to the quarter ended Mar 31, 2014.
• On a year-over-year basis, Revenue has increased in each of the last six quarters, with growth averaging 122.8% over the last eight quarters.
• The strongest year-over-year quarter for Revenue in the past five years was the quarter ended Mar 31, 2022, with growth of 751.6%; the weakest was the quarter ended Dec 31, 2022, with a decline of 76.3%.
• According to Business Quant data, Revenue for the three prior quarters was $288.71 million (quarter ended Mar 31, 2026), $288.1 million (quarter ended Dec 31, 2025) and $249.75 million (quarter ended Sep 30, 2025).